For the third quarter of 2026, analysts anticipate Treace Medical Concepts will report revenue of $51.8 million and an EPS of -$0.25, with the current stock price of $6.45 trading significantly below the average analyst price target of $8.50. Investors are primarily focused on the growth of procedure volumes for the flagship Lapiplasty system as the company navigates an increasingly competitive landscape for bunion correction technologies.
Recent performance has been influenced by the commercial rollout of the SpeedPlate fixation platform and the integration of new technologies into the company’s direct sales model. Market participants are closely monitoring whether Treace can maintain its market-leading position while demonstrating a clear path toward profitability through narrowed operating losses.